Business Wire

PubMatic and Adelphic Partner for Supply Path Optimization

Jaa

PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today announced its partnership with Adelphic, a Viant people-based demand-side platform (DSP). Through this supply path optimization (SPO) partnership, PubMatic and Adelphic have created a more efficient and effective path for Adelphic’s advertisers to access high quality ad inventory.

The growth of the digital advertising ecosystem has led to a rise in impression volume on both the sell and buy sides. To offer a transparent, direct, and fraud-free path to supply, DSPs must be proactive to detect duplicative and fraudulent inventory in the marketplace. By partnering with PubMatic, Adelphic is buying through optimized supply integrations in order to effectively manage queries per second (QPS) and infrastructure costs.

Through this partnership, Adelphic and PubMatic have increased user match rates, resulting in significantly driving improved audience targeting capability. By conducting brand-safety checks, utilizing a rigorous approach to eliminating ad fraud and inventory screening across multiple formats and platforms, PubMatic is able to capture unique spend for Adelphic’s advertiser clients via a safer, and ultimately more efficient path to supply.

“As a publisher-first company, PubMatic has been investing heavily in delivering high quality and efficient supply to buyers. We believe our QPS throttling solution and match rates are market leading and are excited that Adelphic is finding value in our platform. This partnership helps us further extend those benefits to our joint customers,” said Kyle Dozeman, VP, Advertiser Solutions at PubMatic.

As a result of the partnership, Adelphic’s advertisers have seen improvements in the efficiency and effectiveness of their media spend. Publishers can now expect increased spend from Adelphic’s thousands of advertisers, coupled with cross-channel fraud coverage for display, video and mobile.

Over the past two years, in response to the rise of inventory processing costs for DSPs with the proliferation of header bidding, PubMatic has been developing machine learning and artificial intelligence based solutions for QPS throttling. As a result, PubMatic has been able to significantly increase advertiser spend per unit of QPS, thereby increasing the efficiency of the PubMatic and Adelphic platforms and lowering overall technology costs. Identifying and filtering inventory that was recently driving up QPS with little incremental value for Adelphic has resulted in a 51 percent increase in QPS efficiency, a 132 percent increase in win rate, plus a 2.3X lift in spend.

Efficient supply chains drive performance, so we are constantly looking for partners who can simplify the process and are safe and transparent. Because of PubMatic’s strong header tag penetration, we are able to buy directly from a large pool of leading publishers, thus optimizing our buying path on behalf of our advertisers,” said Jeremy Haft, National Vice President at Adelphic.

About PubMatic

PubMatic is a publisher-focused sell-side platform for an open digital media future. Featuring leading omni-channel revenue automation technology for publishers and enterprise-grade programmatic tools for media buyers, PubMatic's publisher-first approach enables advertisers to access premium inventory at scale. Processing over one trillion ad impressions per month, PubMatic has created a global infrastructure to drive publisher monetization and control over their ad inventory. Since 2006, PubMatic's focus on data and technology innovation has fueled the rise of the programmatic industry as a whole. Headquartered in Redwood City, California, PubMatic operates 13 offices and six data centers worldwide.

PubMatic is a registered trademark of PubMatic, Inc. Other trademarks are the property of their respective owners.

About Adelphic

Adelphic is a leading people-based cross-channel demand-side platform. Adelphic provides an enterprise-ready self-service software solution for agencies, brands and other large media buyers to make meaningful engagements with consumers across all devices and formats. The company’s platform is fully RTB-enabled and delivers global scale through access to all leading inventory providers. Adelphic’s technology overcomes the limitations of user identification across all digital devices, yielding rich, nuanced portraits of real people, instead of cookies. Adelphic is owned by Viant, a subsidiary of Time Inc. For more information, visit adelphic.com.

Contact information

PubMatic
Global Contact
Samson Adepoju, 646-731-9773
Director, Corporate Communications
press@pubmatic.com
or
Adelphic
adelphic@sparkpr.com
adelphic.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 16:33Tiedote

Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for

MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 16:00Tiedote

The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer

CTS Engines Announces Senior Management Hire12.12.2017 16:00Tiedote

CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4

LTI to Offer Blockchain Solution Powered by Microsoft Azure12.12.2017 13:45Tiedote

Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company, announced today the availability of its blockchain-based trade finance solution on Microsoft Azure marketplace. The solution tracks the flow of goods in a value chain, improving transparency across multiple entities involved. It enables accelerated adoption of distributed ledger technologies by bringing together LTI’s deep industry knowledge and blockchain capabilities together with Microsoft’s expertise in cloud-based solutions. Aftab Ullah, Chief Operating Officer, LTI said, "Our vision is to deliver exponential operational efficiencies to the world’s leading companies through digital innovation. LTI’s Blockchain services include end-to-end consulting and implementation and are designed to help transform our clients’ business operations. The collaboration

Munich Re Automation Solutions Ltd. today announced the launch of their latest data analytics and reporting product, ALLFINANZ Insight12.12.2017 12:06Tiedote

Munich Re Automation Solutions Ltd., the leading provider of digital underwriting solutions to the life insurance industry, today announced the launch of their latest data analytics and reporting product, ALLFINANZ Insight. ALLFINANZ Insight is designed to help life insurance companies unlock the insights hidden in their underwriting data using a creative and intuitive interface and 30 years of underwriting expertise built in. A vast amount of data is captured during the new business and underwriting process. Accurately categorising and understanding this data can be hugely valuable as the insights generated will significantly improve the design of underwriting rules, the new business and underwriting process as well as operations and distribution management. ALLFINANZ Insight gives your whole team a clearer, deeper view into their underwriting data. The software uses cutt

New Data for Darzalex®▼(daratumumab) Presented at ASH 2017 Show Feasibility of Subcutaneous Use and Potential of Darzalex as a Treatment for Smouldering Multiple Myeloma12.12.2017 11:00Tiedote

Janssen-Cilag International NV (“Janssen”) today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of Darzalex® (daratumumab) co-formulated with recombinant human hyaluronidase enzyme (daratumumab-SC), was generally well-tolerated, with a 12 percent rate of infusion-related reactions (IRRs), in patients with relapsed or refractory multiple myeloma.1 These data were featured as an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta. Daratumumab is currently approved for intravenous (IV) administration, and results from the PAVO trial serve as the basis for an actively enrolling Phase 3 study comparing subcutaneous administration of daratumumab over 3-5 minutes with the approved IV administration in relapsed and refractory multiple myeloma patients.2 Daratumumab is currently indica

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme